WPI 3171 Pill — WHITE CAPSULE, 10mm — Alendronate

WPI pill photo
View full Alendronate profile
ImprintWPI / 3171
ColourWHITE
ShapeCAPSULE
Size10
StrengthALENDRONATE SODIUM 35 mg
Dosage formTablet
ManufacturerActavis Pharma, Inc.
NDC0591-3171
Schedule—
Availability—
IngredientsALENDRONATE SODIUM[ALENDRONIC ACID]

What does this imprint mean?

The imprint "WPI 3171" is a code stamped or printed on the tablet or capsule by the manufacturer, used to identify the drug, its strength and the maker.

Active ingredient

Alendronate

Uses and warnings

No boxed warning. Key warnings: "Upper gastrointestinal adverse reactions can occur" - patients must follow strict dosing instructions (full glass of water, remain upright at least 30 minutes); "hypocalcemia" must be corrected before starting therapy; "severe bone, joint, or muscle pain" may occur, with discontinuation considered if severe; "osteonecrosis of the jaw has been reported," generally in cancer patients or those with risk factors; and "atypical fractures, including femoral fractures," have been reported with long-term bisphosphonate use.

Indicated for "treatment and prevention of osteoporosis in postmenopausal women," to "increase bone mass in men with osteoporosis," for "treatment of glucocorticoid-induced osteoporosis," and for "treatment of Paget's disease of bone." The label notes that for patients at low risk of fracture, clinicians should "consider drug discontinuation after 3 to 5 years of use."

Read the full drug profile →

How to identify this pill

Similar-looking pills

Other pills of Alendronate

Official references

Source: FDA Structured Product Label via NLM Pillbox archive (retired 2021); source file ab66c2e4-ca55-4e7a-a30e-ab5fd970398f.xml